Latest Authoritative Guidelines on Diffuse Parenchymal Lung Disease
The most recent authoritative guidelines specifically addressing diffuse parenchymal lung disease (DPLD) include the 2026 ACR Appropriateness Criteria® Diffuse Lung Disease update, the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline on Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis, and the 2021 ACR Appropriateness Criteria® Diffuse Lung Disease.
Comprehensive List of Recent Guidelines (2021-2026)
Primary DPLD-Specific Guidelines:
ACR Appropriateness Criteria® Diffuse Lung Disease: 2026 Update 1
- Published: 2026
- Focus: Evidence-based imaging guidelines for suspected and confirmed diffuse lung disease, including initial evaluation, acute exacerbation assessment, and surveillance protocols
ATS/ERS/JRS/ALAT Clinical Practice Guideline: Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in Adults 2
- Published: 2022 (American Journal of Respiratory and Critical Care Medicine)
- Focus: Updated diagnostic criteria for IPF including transbronchial lung cryobiopsy (TBLC), UIP pattern recognition, and management of progressive fibrotic disease
ACR Appropriateness Criteria® Diffuse Lung Disease 3
- Published: 2021
- Focus: Imaging appropriateness for chronic dyspnea, inhalational exposures, and systemic diseases with lung involvement
Related Guidelines Addressing DPLD Components:
ERS/ATS Guidelines for Primary Ciliary Dyskinesia Diagnosis 4
- Published: 2025
- Focus: Unified diagnostic approach for ciliary dysfunction-related lung disease using GRADE methodology
Practical Guidance for CTD-Related Interstitial Lung Disease 5
- Published: 2024
- Focus: Early recognition and follow-up of connective tissue disease-associated ILD, including screening protocols for systemic sclerosis and rheumatoid arthritis
French Practical Guidelines: Diagnosis and Management of Idiopathic Pulmonary Fibrosis 6
- Published: 2014
- Focus: HRCT and histopathological UIP pattern criteria, exclusion of alternative diagnoses
Key Distinguishing Features
The 2026 ACR update 1 represents the most current imaging-focused guideline, establishing protocols for three distinct clinical scenarios: initial suspected disease, acute deterioration, and surveillance. This guideline employs RAND/UCLA Appropriateness Method and GRADE criteria for evidence evaluation.
The 2022 ATS/ERS/JRS/ALAT guideline 2 provides the most recent consensus on histopathological diagnosis, notably addressing the evolving role of TBLC as an alternative to surgical lung biopsy, with specific criteria for UIP and probable UIP patterns in multidisciplinary discussion contexts.
Important Context
The 2003 BTS guideline 7 on "diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults" is mentioned in the evidence but is now over 20 years old and has been superseded by more recent international consensus documents. The field has evolved substantially since then, particularly regarding imaging criteria, genetic testing, and antifibrotic therapies.
Note that several guidelines use overlapping terminology: diffuse lung disease (DLD), diffuse parenchymal lung disease (DPLD), and interstitial lung disease (ILD) are used interchangeably in modern literature 3, 1, 8, though "interstitial" is increasingly recognized as misleading since most pathologies involve alveolar and airway compartments beyond the interstitium.